Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Growth Equity - II | Dead

Total Raised


Last Raised


About Istac

Provider of immunotherapeutic treatments. The company provides immunotherapeutic treatments based on the use of muramylpeptides as immunomodulators. Muramylpeptides such as Murabutide and Muradimetide could be useful in the treatment of diseases like AIDS, hepatitis C, and cancer.

Istac Headquarters Location

1 rue du Professeur Calmette P.O. Box 245

Lille, 59019,


33 1 42 25 27 56

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • When was Istac founded?

    Istac was founded in 1989.

  • Where is Istac's headquarters?

    Istac's headquarters is located at 1 rue du Professeur Calmette, Lille.

  • What is Istac's latest funding round?

    Istac's latest funding round is Growth Equity - II.

  • How much did Istac raise?

    Istac raised a total of $1.1M.

  • Who are the investors of Istac?

    Investors of Istac include Nord Innovation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.